Corporate News

• Overland ADCT BioPharma Enters into a Strategic Partnership with Orient EuroPharma to Address the Unmet Needs of Lymphoma Patients in Taiwan and Singapore
• 2022-07-12

• Overland ADCT BioPharma Announces First Patient Dosed in China with ZYNLONTA® in Combination with Rituximab in Global Phase 3 Clinical Trial
• 2022-07-11

• Overland ADCT Appoints Shirley Xu as Chief Medical Officer
• 2021-10-21

• Overland ADCT BioPharma Announces First Patient Dosed in China with ZYNLONTA® in Pivotal Phase 2 Clinical Trial for Diffuse Large B-cell Lymphoma
• 2021-10-21

• Overland ADCT BioPharma Appoints Eric Koo as Chief Executive Officer
• 2021-10-21

• ADC Therapeutics and Overland Pharmaceuticals Announce Formation of Overland ADCT BioPharma to Develop and Commercialize Lonca and other ADCs for Hematologic and Solid Tumor Indications in Greater China and Singapore
• 2021-10-21